NCT07901270Not yet recruiting
Metabolic Changes in Heart Failure Patients Treated With Vericiguat
Metabolic Remodelling in Worsening Heart Failure Treated With Vericiguat: A Prospective Multi-Omics Study Integrating Cardiac Imaging and Endothelial Function
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
Heart failure is a condition in which the heart cannot pump blood as effectively as it should. It can cause symptoms such as shortness of breath, tiredness, and fluid retention. Vericiguat is a medication used in certain patients with heart failure whose symptoms have recently worsened. The aim of this study is to better understand how vericiguat treatment is associated with changes in metabolism, heart function, and blood vessel health in patients with heart failure. This is a prospective, observational study conducted at a single hospital in Italy. Researchers will collect clinical information and analyze biological samples to investigate changes in molecules involved in energy production, inflammation, and cardiovascular function. Heart imaging and assessments of blood vessel function will also be used to better understand the patients' cardiovascular health. The study will explore whether these biological and cardiovascular measurements are associated with treatment with vericiguat and whether they could help identify patients who may benefit most from this therapy. The results may improve our understanding of heart failure and support more personalized treatment strategies in the future.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 21 Oct 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 1 Nov 2027
- Lead sponsor
- University of Salerno
- Diseases
- Heart failure
- NCT number
- NCT07901270
What you commit to
- Study type: Observational
- Planned participants: 30
- From 1 Nov 2026 to the primary completion date, 1 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment with vericiguat.
Other illness
- Failure or refusal to provide written informed consent.
- Cardiac surgery, coronary interventions, or mitral valve interventions performed before the scheduled follow-up reassessment.
- \-
Age
- Age younger than 18 years.
Other
- Pregnancy or breastfeeding.
- Involvement in the planning or conduct of the study, including study-site personnel.
Who the study is looking for
- Adults aged 18 years or older.
- Hospitalized or outpatient patients with worsening heart failure and left ventricular ejection fraction (LVEF) \<45%.
- Patients receiving guideline-directed medical therapy, including an ACE inhibitor or angiotensin receptor-neprilysin inhibitor (ARNI), a beta-blocker, a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor.
- Patients initiating vericiguat treatment as part of optimization of heart failure therapy according to routine clinical practice.
- Provision of written informed consent before any study-specific procedures.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Azienda Ospedaliera Regionale San Carlo di Potenza Coordinator of this site? Confirm its status | Potenza | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.